LivaNova (NASDAQ:LIVN) Lowered to Buy Rating by StockNews.com

StockNews.com downgraded shares of LivaNova (NASDAQ:LIVN) from a strong-buy rating to a buy rating in a research report sent to investors on Wednesday morning.

Other equities research analysts also recently issued research reports about the company. Robert W. Baird raised their price target on LivaNova from $66.00 to $72.00 and gave the company an “outperform” rating in a report on Thursday, October 31st. Needham & Company LLC reaffirmed a “buy” rating and issued a $75.00 price objective on shares of LivaNova in a report on Monday, November 25th. Baird R W upgraded shares of LivaNova from a “hold” rating to a “strong-buy” rating in a research report on Tuesday, September 17th. The Goldman Sachs Group initiated coverage on LivaNova in a research report on Friday, October 4th. They issued a “buy” rating and a $65.00 target price on the stock. Finally, Mizuho lowered their price target on shares of LivaNova from $80.00 to $70.00 and set an “outperform” rating for the company in a report on Thursday, October 31st. One research analyst has rated the stock with a hold rating, six have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat, LivaNova currently has an average rating of “Buy” and an average target price of $69.17.

LivaNova Price Performance

NASDAQ:LIVN opened at $46.75 on Wednesday. LivaNova has a 52-week low of $43.15 and a 52-week high of $64.47. The company has a market cap of $2.54 billion, a P/E ratio of 111.31 and a beta of 0.98. The company has a debt-to-equity ratio of 0.46, a quick ratio of 2.87 and a current ratio of 3.37. The stock’s 50-day simple moving average is $51.32 and its 200 day simple moving average is $50.92.

Insider Activity at LivaNova

In other news, Director Francesco Bianchi sold 1,250 shares of the stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $50.99, for a total transaction of $63,737.50. Following the completion of the sale, the director now directly owns 7,522 shares in the company, valued at approximately $383,546.78. This represents a 14.25 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.27% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On LivaNova

Institutional investors have recently added to or reduced their stakes in the company. Primecap Management Co. CA lifted its position in LivaNova by 0.7% during the second quarter. Primecap Management Co. CA now owns 5,981,200 shares of the company’s stock valued at $327,889,000 after purchasing an additional 44,049 shares during the period. Point72 Asset Management L.P. lifted its holdings in shares of LivaNova by 62.7% in the 3rd quarter. Point72 Asset Management L.P. now owns 2,092,010 shares of the company’s stock worth $109,914,000 after acquiring an additional 806,374 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of LivaNova by 0.6% during the 3rd quarter. Geode Capital Management LLC now owns 1,344,949 shares of the company’s stock worth $70,676,000 after acquiring an additional 8,331 shares during the last quarter. Victory Capital Management Inc. grew its holdings in shares of LivaNova by 16.6% in the third quarter. Victory Capital Management Inc. now owns 935,102 shares of the company’s stock worth $49,130,000 after purchasing an additional 133,401 shares during the last quarter. Finally, Magnetar Financial LLC raised its position in LivaNova by 8.1% during the 2nd quarter. Magnetar Financial LLC now owns 814,452 shares of the company’s stock valued at $44,648,000 after purchasing an additional 61,114 shares in the last quarter. Institutional investors own 97.64% of the company’s stock.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.